跳至主要内容
临床试验/NCT00087061
NCT00087061已完成1 期

Oral ST1481 in Adults With Malignant Glioma: A Phase I-II Clinical Trial

Jonsson Comprehensive Cancer Center2 个研究点 分布在 1 个国家开始时间: 2004年5月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
试验地点
2

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as gimatecan, work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase I/II trial is studying the side effects and best dose of gimatecan in treating patients with recurrent or progressive primary malignant glioma.

详细描述

OBJECTIVES:

Primary

  • Determine the maximum tolerated dose (MTD) of gimatecan in patients with recurrent or progressive primary malignant glioma treated with or without concurrent enzyme-inducing anticonvulsant drugs.
  • Determine whether this drug has sufficient activity to warrant further development in these patients. (phase II)

Secondary

  • Determine the qualitative and quantitative toxic effects of this drug in these patients.
  • Determine the pharmacokinetic behaviors of this drug in these patients.
  • Correlate the principal toxic effects with the pertinent pharmacokinetic parameters of this drug in these patients.
  • Determine the antitumor activity of this drug in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验